Predictive biomarkers to anti-VEGF therapy: Progress toward an elusive goal

Clinical Cancer Research

Volumn 19, Issue 4, 2013, Pages 755-757

  Gyanchandani, Rekha ^a   Kim, Seungwon ^a,b  

^a University of Pittsburgh School of Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CEDIRANIB; CYTOKINE; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN 110; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DRUG PROTEIN BINDING; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874069630     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3585     Document Type: Article

References (13)

1. Hegde PS, Jubb AM, Chen D, Li NF, Meng G, Bernaards C, et al. Predictive impact of circulating vascular endothelial growth factor in 4 phase III trials evaluating bevacizumab. Clin Cancer Res 2013;19: 929-37.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
3. Sadler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2524-50.
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for the treatment of metastatic renal cell carcinoma: a randomised, double-blinded phase III trial. Lancet 2007;370:2103-11.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 2007;357:2666-76.
6. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
7. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with our without bevacizumab for first-line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
8. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin- 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24:217-27.
9. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-78.
10. Miles DW, de Haas SL, Dirix LX, Chan A, Pivot X, Tomczak P, et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab+docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium; 2010. San Antonio, TX. Abstract P2-16-04.
11. Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, et al. Association between VEGF splice isoforms and progression free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18:6384-6391.
12. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013;24:220-5.
13. Christopoulos A, Ahn SM, Klein JD, Kim S. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 2011;33:1220-9.